RecruitingNot ApplicableNCT04045470

A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma


Sponsor

Dana-Farber Cancer Institute

Enrollment

20 participants

Start Date

Dec 11, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

This research is being done to study the safety of implanting and retrieving a microdevice that releases up to 19 drugs directly within a cancerous lesion as a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma and peripheral T cell lymphoma


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study uses a tiny implantable device (a microdevice about the size of a grain of rice) that is placed directly into a tumor. The device releases tiny amounts of multiple different drugs at once, allowing researchers to see which drugs actually kill that specific patient's cancer cells — right inside the body. This could help personalize cancer treatment. **You may be eligible if...** - You have a solid tumor (such as breast, pancreatic, or other cancer) that is accessible for a biopsy or minor procedure - You are scheduled for surgery or a biopsy where the device can be inserted and retrieved - You are 18 or older and able to provide consent **You may NOT be eligible if...** - Your tumor is not accessible for the device insertion procedure - You have certain clotting problems or are on blood thinners that cannot be safely stopped - You are pregnant - You have allergies to any of the drugs being tested in the device Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEMicrodevices

The microdevice was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer.

OTHERStandard of care therapy

Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy

OTHERStandard of care systemic therapy

Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which must include a systemic therapy.


Locations(1)

Dana Farber Cancer Institute

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04045470


Related Trials